Antiviral vaccines with improved cellular immunogenicity
AssigneesBeth Israel Deaconess Medical Center, Inc., Los Alamos National Security, LLC
InventorsDan H. Barouch, Bette T. Korber, William M. Fischer
Life of this patent
Estimating the term…
Abstract
The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
Claims23
An immunogenic composition comprising at least two distinct optimized viral polypeptides, wherein said optimized viral polypeptides correspond to the same viral gene product, wherein the viral gene product is selected from the group consisting of gag, pol, and env, and
- wherein the at least two distinct optimized gag polypeptides are selected from any one or more of the groups:
- (a) SEQ ID NO:
- 3 and 4, (b) SEQ ID NO:
- 3, and 15 (c) SEQ ID NO:
- 4 and 15;
- wherein the at least two distinct optimized pol polypeptides are selected from any one or more of the groups:
- (a) SEQ ID NO:
- 12 and 13, (b) SEQ ID NO:
- 12 and 14, (c) SEQ ID NO:
- 13 and 14;
- and
- wherein the at least two distinct optimized env polypeptides are selected from any one or more of the groups:
- (a) SEQ ID NO:
- 9 and 10, (b) SEQ ID NO:
- 9 and 11, (c) SEQ ID NO:
- 10 and 11.
A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.